FOXO (FOXO Technologies) Beta: 3.0993 (As of Jun. 24, 2026)


What is FOXO Technologies Beta?

FOXO Technologies FOXO -50.00% Beta is 3.0993 as of Jun. 24, 2026. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), FOXO Technologies's Beta is 3.0993.

FOXO Technologies  (OTCPK:FOXO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

FOXO Technologies Beta Related Terms

FOXO Technologies Beta Historical Data

* Premium members only.

The historical data trend for FOXO Technologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FOXO Technologies Beta Chart

FOXO Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 6.63

FOXO Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 4.79 6.63 2.89

FOXO vs WORX, MSPR, ESSID: Beta Comparison

For the Health Information Services subindustry, FOXO Technologies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FOXO Technologies Beta vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, FOXO Technologies's Beta distribution charts can be found below:

* The bar in red indicates where FOXO Technologies's Beta falls into.


FOXO Technologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.0993 mean?
FOXO Technologies (FOXO) has a Beta of 3.0993 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for FOXO Technologies and its competitors.
Is FOXO Technologies' Beta too high?
FOXO Technologies' current Beta is 3.0993.
How does FOXO Technologies' Beta compare to WORX and MSPR?
FOXO Technologies' Beta of 3.0993 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for FOXO Technologies and its competitors. FOXO Technologies's current Beta is 3.0993. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FOXO Technologies stock overvalued right now?
Based on GuruFocus' analysis, FOXO Technologies (FOXO) is currently considered Possible Value Trap. The stock's GF Value™ is $5.87, compared to a current price of $0.00 — trading 100% below its estimated fair value. The current Beta is 3.0993. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For FOXO Technologies (FOXO), the current Beta is 3.0993 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FOXO Technologies Business Description

Address 477 South Rosemary Avenue, Suite 224, West Palm Beach, FL, USA, 33401
FOXO Technologies Inc is a healthcare services and technology company. It currently operates four synergistic divisions: (i) a rural hospital division; (ii) a mental and behavioral health division; (iii) an information, data and biospecimen sourcing division; and (iv) an epigenetics diagnostics and interpretation division. The Company manages and classifies its business into three reportable business segments: (i) Healthcare, (ii) Life Science Services and (iii) Labs. Myrtle, RCHI and SCCH operate under the Healthcare segment and Vector operates under the Life Science Services segment. The company generates majority of its revenue from Healthcare segment. It includes RCHI's hospital, BSF, has 25 inpatient beds, and a 24/7 emergency department and provides ancillary services.